Abeona Therapeutics and REGENXBIO Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector Nov 5, 2018
Abeona Therapeutics Appoints João Siffert, M.D. Head of Research and Development and Chief Medical Officer Oct 18, 2018
Abeona Therapeutics Announces Authorization to Commence Phase 1/2 Gene Therapy Clinical Study for Patients with MPS IIIB in Spain Sep 12, 2018
Abeona Therapeutics Reports Second Quarter 2018 Financial Results and Business Highlights Aug 9, 2018
Abeona Therapeutics Announces Leadership Appointments with Max Colao as Chief Commercial Officer Jul 26, 2018
Abeona Therapeutics Announces Upcoming Presentation at Jefferies 2018 Global Healthcare Conference Jun 6, 2018
